Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1358-1366

  Mayordomo, Cristina ^a   García Recio, Susana ^a   Ametller, Elisabet ^a   Fernández Nogueira, Patricia ^a   Pastor Arroyo, Eva María ^a   Vinyals, Laia ^a   Casas, Ignasi ^a   Gascón, Pedro ^a   Almendro, Vanessa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SUBSTANCE P; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN COS7; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEADY STATE;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIGANDS; MALE; NEOPLASMS; PIPERIDINES; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, NEUROKININ-1; SIGNAL TRANSDUCTION; SUBSTANCE P;

EID: 84855753457     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22848     Document Type: Article

References (43)

1. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM. 2009. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109:1079-1086.
2. Almendro V, Ametller E, Garcia-Recio S, Collazo O, Casas I, Auge JM, Maurel J, Gascon P. 2009. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One 4:e4728.
3. Almendro V, Garcia-Recio S, Gascon P. 2010. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets 11:1169-1180.
4. Bost KL. 2004. Tachykinin-mediated modulation of the immune response. Front Biosci 9:3331-3332.
5. Castagliuolo I, Valenick L, Liu J, Pothoulakis C. 2000. Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 275:26545-26550.
6. Castro TA, Cohen MC, Rameshwar P. 2005. The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential. Clin Exp Metastasis 22:621-628.
7. Eglezos A, Andrews PV, Boyd RL, Helme RD. 1991. Modulation of the immune response by tachykinins. Immunol Cell Biol 69:285-294.
8. Faber AC, Wong KK, Engelman JA. 2010. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 9:851-852.
9. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. 2004. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24:200-216.
10. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X. 1997. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385.
11. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW. 2003. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 83:731-742.
12. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. 2010. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70:2235-2244.
13. Hoffmann T, Bos M, Stadler H, Schnider P, Hunkeler W, Godel T, Galley G, Ballard TM, Higgins GA, Poli SM, Sleight AJ. 2006. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett 16:1362-1365.
14. Huang SC, Korlipara VL. 2010. Neurokinin-1 receptor antagonists: A comprehensive patent survey. Expert Opin Ther Pat 20:1019-1045.
15. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT. 2010. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70:1053-1062.
16. Humphrey JM. 2003. Medicinal chemistry of selective neurokinin-1 antagonists. Curr Top Med Chem 3:1423-1435.
17. Jeng AY, Fujimoto RA, Chou M, Tan J, Erion MD. 1997. Suppression of substance P biosynthesis in sensory neurons of dorsal root ganglion by prodrug esters of potent peptidylglycine alpha-amidating monooxygenase inhibitors. J Biol Chem 272:14666-14671.
18. Joshi DD, Dang A, Yadav P, Qian J, Bandari PS, Chen K, Donnelly R, Castro T, Gascon P, Haider A, Rameshwar P. 2001. Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: A combined functional and proteomic study. Blood 98:2697-2706.
19. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. 2006. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639.
20. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C. 2004. Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 279:45519-45527.
21. Le XF, Pruefer F, Bast RC, Jr. 2005. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4:87-95.
22. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. 2001. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61:6583-6591.
23. Liang W, Kujawski M, Wu J, Lu J, Herrmann A, Loera S, Yen Y, Lee F, Yu H, Wen W, Jove R. 2010. Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res 16:924-935.
24. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. 2009. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 69:6871-6878.
25. Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI, Vigna SR, Maggio JE, et al. 1995. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268:1629-1632.
26. Matsas R, Fulcher IS, Kenny AJ, Turner AJ. 1983. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc Natl Acad Sci USA 80:3111-3115.
27. Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. 2009. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15:7266-7276.
28. Modly CE, Das M, Don PS, Marcelo CL, Mukhtar H, Bickers DR. 1986. Capsaicin as an in vitro inhibitor of benzo(a)pyrene metabolism and its DNA binding in human and murine keratinocytes. Drug Metab Dispos 14:413-416.
29. Munoz M, Perez A, Covenas R, Rosso M, Castro E. 2004a. Antitumoural action of L-733, 060 on neuroblastoma and glioma cell lines. Arch Ital Biol 142:105-112.
30. Munoz M, Perez A, Rosso M, Zamarriego C, Rosso R. 2004b. Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res 14:183-188.
31. Muñoz M, Rosso M, Coveñas R. 2011. The NK-1 receptor: A new target in cancer therapy. Curr Drug Targets 12:909-921.
32. New DC, Wong YH. 2007. Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal 2:2.
33. Nieber K, Oehme P, Arefolov VA, Valdman AV. 1988. Effect of the N-terminal tetrapeptide of substance P SP (1-4) and tuftsin on the pre- and postsynaptic transmitter outflow in rat adrenal gland slices. Biomed Biochim Acta 47:663-666.
34. Palma C. 2006. Tachykinins and their receptors in human malignancies. Curr Drug Targets 7:1043-1052.
35. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S. 2000. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82:480-487.
36. Patel HJ, Ramkissoon SH, Patel PS, Rameshwar P. 2005. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc Natl Acad Sci USA 102:17436-17441.
37. Quartara L, Altamura M. 2006. Tachykinin receptors antagonists: From research to clinic. Curr Drug Targets 7:975-992.
38. Rao G, Patel PS, Idler SP, Maloof P, Gascon P, Potian JA, Rameshwar P. 2004. Facilitating role of preprotachykinin-I gene in the integration of breast cancer cells within the stromal compartment of the bone marrow: A model of early cancer progression. Cancer Res 64:2874-2881.
39. Rosso M, Robles-Frias MJ, Covenas R, Salinas-Martin MV, Munoz M. 2008. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733, 060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 29:245-254.
40. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. 2002. The tachykinin peptide family. Pharmacol Rev 54:285-322.
41. Singh D, Joshi DD, Hameed M, Qian J, Gascon P, Maloof PB, Mosenthal A, Rameshwar P. 2000. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 97:388-393.
42. Singh AS, Caplan A, Corcoran KE, Fernandez JS, Preziosi M, Rameshwar P. 2006. Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. Vascul Pharmacol 45:235-242.
43. Yamaguchi K, Kugimiya T, Miyazaki T. 2005. Substance P receptor in U373 MG human astrocytoma cells activates mitogen-activated protein kinases ERK1/2 through Src. Brain Tumor Pathol 22:1-8.